CA3090088C - Vaccin polyvalent contre les infections a alphavirus de salmonide - Google Patents

Vaccin polyvalent contre les infections a alphavirus de salmonide Download PDF

Info

Publication number
CA3090088C
CA3090088C CA3090088A CA3090088A CA3090088C CA 3090088 C CA3090088 C CA 3090088C CA 3090088 A CA3090088 A CA 3090088A CA 3090088 A CA3090088 A CA 3090088A CA 3090088 C CA3090088 C CA 3090088C
Authority
CA
Canada
Prior art keywords
virus
inactivated
cells
salmonid alphavirus
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3090088A
Other languages
English (en)
Other versions
CA3090088A1 (fr
Inventor
Svein Alexandersen
Trygve Meum Eliassen
Inge Tom Solbakk
Marit Rode
Bernt Martinsen
Anne Aas-Eng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmaq AS
Original Assignee
Pharmaq AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40469649&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3090088(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmaq AS filed Critical Pharmaq AS
Publication of CA3090088A1 publication Critical patent/CA3090088A1/fr
Application granted granted Critical
Publication of CA3090088C publication Critical patent/CA3090088C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/107—Vibrio
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/116—Polyvalent bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1808—Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE, semliki forest virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36161—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne une composition comprenant un arbovirus de salmonidé ou un matériau antigénique et/ou immunogénique dérivé combiné avec un ou plusieurs composants sélectionnés dans le groupe contenant les éléments suivants : une bactérie vivante, atténuée ou tuée, un virus autre que larbovirus de salmonidé, ledit virus étant de préférence atténué ou inactif, un champignon, un parasite et un matériau antigénique et/ou immunogénique dérivé de nimporte lequel de ces composants. Linvention concerne également une forme de dosage et un vaccin comprenant ladite composition, de même que lutilisation de la composition en médecine. Linvention concerne aussi une méthode de fabrication dune composition ou dun vaccin décrits ci-dessus et une méthode pour améliorer un vaccin polyvalent en y ajoutant un arbovirus de salmonidé atténué ou inactif. Date reçue / Date Received 2020-08-14
CA3090088A 2008-02-08 2009-02-06 Vaccin polyvalent contre les infections a alphavirus de salmonide Active CA3090088C (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
NO20080711 2008-02-08
NO20080711 2008-02-08
NO20080885 2008-02-20
NO20080885 2008-02-20
NO20090290A NO333242B1 (no) 2008-02-08 2009-01-20 Sammensetning, medisinsk anvendelse og fremgangsmate som omfatter salmonid alfavirus
NO20090290 2009-01-20
CA2653300A CA2653300C (fr) 2008-02-08 2009-02-06 Vaccin polyvalent contre les infections a alphavirus de salmonide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2653300A Division CA2653300C (fr) 2008-02-08 2009-02-06 Vaccin polyvalent contre les infections a alphavirus de salmonide

Publications (2)

Publication Number Publication Date
CA3090088A1 CA3090088A1 (fr) 2009-08-08
CA3090088C true CA3090088C (fr) 2023-01-31

Family

ID=40469649

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2653300A Active CA2653300C (fr) 2008-02-08 2009-02-06 Vaccin polyvalent contre les infections a alphavirus de salmonide
CA3090088A Active CA3090088C (fr) 2008-02-08 2009-02-06 Vaccin polyvalent contre les infections a alphavirus de salmonide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2653300A Active CA2653300C (fr) 2008-02-08 2009-02-06 Vaccin polyvalent contre les infections a alphavirus de salmonide

Country Status (4)

Country Link
CA (2) CA2653300C (fr)
CL (1) CL2009000287A1 (fr)
GB (2) GB2493662B (fr)
NO (2) NO333242B1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012130723A1 (fr) 2011-03-25 2012-10-04 Intervet International B.V. Vaccin contre les alphavirus des salmonidés
WO2014041189A1 (fr) * 2012-09-17 2014-03-20 Novartis Ag Alphavirus de salmonidé et ses utilisations
NO344938B1 (en) * 2018-12-13 2020-07-20 Patogen As Pancreas Disease Virus Markers
BE1028701B1 (nl) * 2020-10-13 2022-05-16 Poulpharm Bvba Werkwijze voor autovaccin productie en verkregen autovaccin
CN112877399B (zh) * 2021-01-20 2023-05-16 中国水产科学研究院黑龙江水产研究所 一种鲑鳟鱼致病菌药敏检测方法、药敏检测试剂盒及制备方法
WO2023034804A1 (fr) * 2021-08-31 2023-03-09 Zoetis Services Llc Alphavirus atténué

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69531891D1 (de) * 1994-10-18 2003-11-13 Akzo Nobel Nv Virus, welches die Pankreas-Krankheit bei Fischen verursacht
ATE369429T1 (de) * 1998-05-08 2007-08-15 Intervet Int Bv Strukturproteine des virus, welches die pankreas- krankheit bei fischen verursacht, und ihre verwendungen
WO2003101482A2 (fr) * 2002-05-31 2003-12-11 Genesis Group Inc. Formulations de vaccins associes a des liposomes, destinees a des poissons a nageoires
DK179025B1 (da) * 2005-09-16 2017-08-28 Intervet Int Bv Fiskevaccine
GB2452892B (en) * 2006-06-29 2011-10-12 Pharmaq As Process for culturing bacteria of the piscirickettsia genus

Also Published As

Publication number Publication date
GB0901913D0 (en) 2009-03-11
CA2653300A1 (fr) 2009-08-08
CA3090088A1 (fr) 2009-08-08
GB2457158B (en) 2013-04-03
GB2493662B (en) 2013-04-17
GB2493662A (en) 2013-02-13
NO2015019I1 (no) 2015-08-10
NO20090290L (no) 2009-08-10
GB2457158A (en) 2009-08-12
NO333242B1 (no) 2013-04-15
CL2009000287A1 (es) 2010-08-27
CA2653300C (fr) 2020-11-17
GB201219654D0 (en) 2012-12-12

Similar Documents

Publication Publication Date Title
Urbano et al. African swine fever control and prevention: an update on vaccine development
CA3090088C (fr) Vaccin polyvalent contre les infections a alphavirus de salmonide
US8524249B2 (en) Vaccines for inclusion body hepatitis
Hsieh et al. DNA-mediated vaccination conferring protection against infectious bursal disease in broiler chickens in the presence of maternal antibody
Van de Water et al. VP2 exchange and NS3/NS3a deletion in African horse sickness virus (AHSV) in development of disabled infectious single animal vaccine candidates for AHSV
US20210269488A1 (en) Recombinant rotavirus expression system and recombinant rotaviruses
US20160122728A1 (en) Ipn vaccine
KR100737434B1 (ko) 돼지전염성위장염바이러스, 유행성설사바이러스 및로타바이러스의 혼합생백신 및 이를 이용한 백신접종방법
JP4664901B2 (ja) 不活性化ノダウイルスワクチン
NO346254B1 (no) Isolert salmonid alfavirus og anvendelse derav
JP4373916B2 (ja) ニワトリ２型アストロウイルス
Rimstad Vaccination against infectious pancreatic necrosis
US20050169939A1 (en) Chicken anemia virus vaccine from cell line
NO20130080L (no) Polyvalent vaksine mot salmonid alfavirusinfeksjoner
AU2014201189B2 (en) Method for producing vaccinal viral strain of a virus of the Reoviridae family
EP2640832B1 (fr) Nouvel agent étiologique
US9402891B2 (en) Norovirus immunogens and related materials and methods
US10688176B2 (en) Reoviridae vaccine
WO2024003035A1 (fr) Vaccins contre la piscirickettsiose (septicémie rickettsienne des salmonidés)
JP3040157B2 (ja) イヌパルボウイルス（ｃｐｖ）を含む弱毒イヌパルボウイルスワクチンとイヌ科動物におけるｃｐｖ感染予防
Sharma Development and Evaluation of Vaccine Candidates for Senecavirus A
AU2002332925A1 (en) Chicken anemia virus vaccine from cell line

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200814

EEER Examination request

Effective date: 20200814

EEER Examination request

Effective date: 20200814

EEER Examination request

Effective date: 20200814

EEER Examination request

Effective date: 20200814